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Abstract 29	
Purpose Patients admitted to Intensive Care Unit (ICU) with K. pneumoniae infections are characterized by high 30	
mortality. The aims of the present study were to investigate the population pharmacokinetics parameters and to assess the 31	
probability of target attainment of meropenem in critically ill patients to provide information for more effective regimens. 32	
Methods Twenty-seven consecutive patients were included in the study. Meropenem was administered as 3-h intravenous 33	
(i.v.) infusions at doses of 1-2 g every 8 or 12 h. Meropenem plasma concentrations were measured by an HPLC method 34	
and a population pharmacokinetics analysis was performed using NONMEM software. Meropenem plasma disposition 35	
was simulated for extended (3-h; 5-h) or continuous i.v. infusions, and the following parameters were calculated: time 36	
during which free drug concentrations were above MIC (fT>MIC), free minimum plasma concentrations above 4×MIC 37	
(fCmin>4×MIC), Probability of Target Attainment (PTA) and Cumulative Fraction of Response (CFR).  38	
Results Gender and severity of sepsis affected meropenem clearance, whose typical population values ranged from 6.22 39	
up to 12.04 L/h (mean±SD value, 9.38±4.47 L/h). Mean Cmin value was 7.90±7.91 mg/L, suggesting a high inter-40	
individual variability. The simulation confirmed that 88% and 97.5% of patients achieved effective Cmin>4xMIC values 41	
after 3-h and 5-h i.v. infusions of meropenem 2gx3/day, respectively. On the contrary, the same total daily doses reached 42	
the target Cmin>4xMIC values in 100% of patients when administered as continuous i.v. infusions. 43	
Conclusions Several factors may influence meropenem pharmacokinetics in ICU patients. Continuous i.v. infusions of 44	
meropenem seems to be more effective than standard regimens to achieve optimal therapeutic targets.  45	
 46	
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 Introduction 51	
The development of infections in critically ill patients is a dramatic problem since mortality and morbidity rates remain 52	
high. Moreover, the antibiotic therapy may not be always effective, because pathophysiological changes associated with 53	
the course of the disease may often alter drug pharmacokinetics [1-2]. 54	
Meropenem is a broad-spectrum beta-lactam antibiotic widely used for the treatment of nosocomial infections, due to its 55	
rapid and good distribution in most body tissues and fluids [3,4]. From a pharmacokinetic/pharmacodynamic (PK/PD) 56	
point of view, meropenem is a time-dependent antibacterial drug, whose efficacy is predicted by the time during which 57	
the free drug plasma concentration is maintained above the minimum inhibitory concentration (MIC) between two 58	
consecutive doses (fT>MIC) [5-8]. To ensure a bactericidal effect, the fT>MIC should be higher than 40% [9]. 59	
Furthermore, efficacy may be anticipated by the minimum plasma concentration (Cmin) targeted to values at least 4 times 60	
the MIC value (Cmin>4×MIC) [10].  61	
Previous studies suggest that the pharmacokinetics of meropenem in critically ill patients differs to healthy volunteers 62	
[1]. In fact, pathophysiological changes in patients admitted to intensive care units (ICUs) have a profound effect on both 63	
volume of distribution (V) and clearance (Cl) of meropenem [11], thus reducing the percentage of patients who may reach 64	
the PK/PD target values associated with a therapeutic benefit. Therefore, a TDM-guided antimicrobial therapy may 65	
minimize pharmacokinetic variability and maximize therapeutic benefits. Such a strategy may spare critically ill patients 66	
from therapeutic failures due to the unpredictable pharmacokinetics and prevent the occurrence of resistance due to 67	
suboptimal dosages [12,13]. In addition, the development of a meropenem population pharmacokinetic (POP/PK) model 68	
in critically ill patients may be considered a rational approach to optimize individual dosing regimens [14,15]. 69	
The main aims of the present study were: 1) to develop a POP/PK model of meropenem in patients admitted to Intensive 70	
Care Unit (ICU) and 2) to define a PK/PD target attainment (PTA) for different administration schedules. 71	
 72	
Patients and methods 73	
 74	
Patients and anti-infective treatment 75	
The present study was a prospective, monocentric trial, conducted at the IRCCS AOU San Martino-IST Hospital, Genoa, 76	
Italy. The study consecutively enrolled patients with sepsis, severe sepsis or septic shock (according to the definitions of 77	
the American College of Critical Care Medicine Consensus Conference Committee - 2001 78	
SCCM/ESICM/ACCP/ATS/SIS) [16], admitted to the ICU wards. Inclusion criteria were as follows: patients admitted to 79	
ICUs who developed a Klebsiella pneumoniae (KP) nosocomial infection treated with meropenem alone or in 80	
combination depending on the resistance profile of the bacterial strain; meropenem administration for at least 2 days; 81	
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bacteremia confirmed by at least one positive blood culture. Patients undergoing dialysis procedures were excluded. The 82	
study was approved by the Ethics Committee of the IRCCS AOU San Martino-IST Hospital and a signed informed 83	
consent from patients or their relatives was obtained before enrolment, according to local regulations and Ethics 84	
Committee recommendations. 85	
Individual meropenem dose was decided by infectivologists on the basis of clinical indications, infection severity and 86	
sensitivity of bacterial strain. The Vitek 2 automated system (bioMérieux, Marcy L’Etoile, France) was used for 87	
identification and antimicrobial susceptibility testing of bacterial strain; minimum inhibitory concentrations (MICs) were 88	
classified according to established breakpoints by Performance Standards for Antimicrobial Susceptibility Testing: 89	
Twenty-second Informational Supplement (Clinical and laboratory standards Institute [CLSI] M100-S22) [17]. Patients 90	
received conventional dosing of meropenem (1 or 2 g) as an intravenous 3-h infusion two or three times a day. Further 91	
dose adjustment was considered in enrolled patients according to creatinine clearance when required and under the 92	
supervision of the infectivologists. 93	
 94	
Pharmacokinetic sampling and concentrations analysis 95	
Meropenem plasma concentrations were determined for each patient, after at least three completed infusions of the drug 96	
(second day); blood samples were collected according to the following scheme: immediately after the end of infusion, 1, 97	
3, 5 hours after the end of infusion and immediately before next administration of meropenem. For each sample, an aliquot 98	
of 4 mL of blood was drawn into heparinized tubes, which were centrifuged at 1000 g for 10 min and the resulting plasma 99	
was stored at -80 °C. Sample analysis was performed at the Clinical Pharmacology and Toxicology Unit, University of 100	
Genoa. 101	
Meropenem plasma concentrations were determined with a validated high-performance liquid chromatography (HPLC) 102	
method previously described by Legrand et al. [18], with minor modifications (see Supplementary Material). 103	
The calibration curves of peak areas vs. meropenem concentrations were linear from 0.5 up to 100 mg/L, giving a 104	
correlation coefficient r2 = 0.999. The results, as far as precision and accuracy, are concerned, are derived from the 105	
measured concentrations of the validation samples, and were acceptable according to The International Conference on 106	
Harmonisation (ICH) Harmonised Tripartite Guideline Q2(R1) and Washington criteria [19,20]. 107	
 108	
Population pharmacokinetic analysis 109	
Pharmacokinetic analysis of meropenem plasma concentrations was performed according to a non-linear mixed-effects 110	
modeling approach using NONMEM vers. 7.2 software [21], together with PsN and Xpose4 packages [22,23]. All 111	
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concentration values were adjusted to their respective 98% values in order to take into account the plasma protein binding 112	
of meropenem, which is approximately 2% of total plasma concentration.  113	
From the initial model (one-compartment, first-order elimination with additive error model) several possible 114	
combinations of structural and stochastic models were evaluated (one- and two-compartment, first-order and non-linear 115	
elimination with additive, proportional and mixed error models), as well as the interindividual variability (IIV) of 116	
pharmacokinetic parameters. The following covariates were tested within the models: gender, age, height, weight, body 117	
mass index, serum creatinine, creatinine clearance (calculated according the Cockcroft and Gault formula), serum 118	
albumin, severity of sepsis (i.e., sepsis, severe sepsis or septic shock). A generalized additive modeling (GAM) using the 119	
Xpose4 package screened the covariates for their leverage on pharmacokinetic parameters of meropenem [24] and then 120	
they were included stepwise with backward elimination from the final model. In particular, continuous variables were 121	
centered on their median value and their effect was evaluated by linear and non-linear relationships (i.e., piecewise linear, 122	
exponential and power models). The improvement across the different models was judged by a decrease in objective 123	
function value (OFV) greater than 3.81 units (p<0.05), while a decrease of 6.63 points was adopted in backward exclusion 124	
(p<0.01). The difference in OFV (ΔOFV) was reported for all models with respect to the former basic model (i.e., 1-125	
compartment model with additive error model, without IIV and covariates). The Xpose4 package was used to evaluate 126	
model performance by goodness-of-fit plots, visual predictive check (VPC), and bootstrap results from 4000 simulated 127	
datasets. Finally, eta-shrinkage values were calculated to identify and quantify model overfitting. 128	
The final model was used to simulate meropenem plasma disposition in 4000 patients according to the procedure 129	
previously described [8]. In particular, sex and severity of sepsis were chosen in a random manner by appropriate 130	
command lines included within the NONMEM control file. In a similar way, patient’s age and serum albumin values 131	
were obtained according to value distribution of the corresponding parameter in the original population enrolled in the 132	
present study. Moreover, dosing regimens of meropenem were investigated as 3-h and 5-h i.v. infusions (1-g or 2-g doses 133	
two or three times per day), or continuous infusions (3-g or 6-g doses per day). For all of these regimens, fT>MIC and 134	
fCmin>4×MIC values were calculated in simulated patients. For every simulated patient, the individual fT>MIC (fT>MICi) 135	
value was obtained according the following formula: 136	
%fT>MICi = LN(dose/(Vi×MIC))×(Vi/Cli)×(100/DI) 137	
where LN is the natural logarithm, Cli and Vi are respectively individual drug clearance and volume of distribution, DI is 138	
the time interval between two consecutive doses (i.e., 8 or 12 h) [25]. For the calculation of fCmin>4×MIC values, the 139	
predicted Cmin values were directly obtained from NONMEM output. For both PK/PD parameters, the probability of 140	
target attainment (PTA) and cumulative fraction of response (CFR) were calculated according to Mouton et al. [8], on the 141	
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basis of EUCAST MIC value distribution [26] (see Supplementary Table 1). A threshold value for PTA of 95% was 142	
considered to compare results among the different schedules of drug administration investigated in the present simulation. 143	
 144	
Statistics 145	
Demographic data of patients, covariates and study results are presented as mean±standard deviation (S.D.) or median 146	
values and range (or 95% confidence interval), on the basis of the parameter described. Unpaired Student’s t test was 147	
used to compare variables according to gender. A P value lower than 0.05 was considered to be statistically significant. 148	
As stated above, the final population pharmacokinetic model was used to fit the observed data obtained after a 3-h infusion 149	
and to simulate the pharmacokinetic parameters after continuous infusions. The aim was to investigate whether the 150	
continuous infusions gave an advantage in the attainment of PK/PD target values over the extented infusions. Therefore, 151	
sample size was calculated by considering an α error of 0.5, a power of 0.8 and a mean difference of at least 15% (±15% 152	
as standard deviation) in the main PK/PD parameters between the observed 3-h extended infusions and the simulated 5-153	
h extended and continuous infusions of meropenem. Twenty patients were required to be enrolled to reject the null 154	
hypothesis that the difference was zero.  155	
 156	
Results 157	
The present study was conducted on 27 consecutive patients admitted to different ICUs of IRCCS AOU San Martino-IST 158	
Hospital, Genoa, from April 2013 to December 2014. All of the patients received meropenem 2-6 g/day as 3-h i.v. 159	
infusions alone (2 patients) or in association with colistin + tigecycline (7 patients), gentamicin + tigecycline (14 patients), 160	
gentamicin + tigecycline + fosfomycin (1 patient), gentamicin + tigecycline + ertapenem (2 patients), tigecycline + 161	
ertapenem (1 patient). Only 1 patient received meropenem 9 g/day.  162	
Main characteristics and descriptive statistics of principal covariates investigated in our patients are reported in Table 1, 163	
and significant gender differences were observed for body weight, height and body surface area. The table also reports 164	
number of patients with sepsis, severe sepsis or septic shock, severity-of-disease according to APACHE II classification 165	
(Acute Physiology And Chronic Health Evaluation) [27] and SAPS II Score (Simplified Acute Physiology Score) [28], 166	
Charlson comorbidity index [29], Glasgow coma scale (GCS), and meropenem dosage. Twenty-eight days after the 167	
admission to Intensive Care Unit, five of the 27 patients (18.5%) died.  168	
 169	
Population pharmacokinetic analysis and simulation 170	
One hundred and eighteen blood samples were obtained after the administration of a meropenem dose at steady state in 171	
27 patients (median number of samples per patient, 4, range 2-5). Clinical records of some patients were lacking of 172	
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covariate values (i.e., height, body weight, serum albumin, serum creatinine in 2, 1, 1, 1 subjects, respectively). In those 173	
cases, the gender-related median value of the covariate was adopted. 174	
The final model was a one-compartment model with mixed error model and IIV for both Cl and V. The mixed error model 175	
(run 003) was associated with a significant improvement (ΔOFV=-35.24) with respect to the additive (the first model) 176	
and proportional error model (ΔOFV=-27.54, run 002). Interestingly, a 2-compartment model did not achieve a significant 177	
improvement in terms of ΔOFV (-2.90, run 004) with respect to the corresponding 1-compartment model. Further 178	
improvement was observed after the introduction of IIV for Cl, alone (ΔOFV=-71.51, run 006) and in combination with 179	
IIV for V (ΔOFV=-116.40, run 007). As stated above, the modelling procedure was guided by the GAM analysis 180	
performed on both Cl and V, and several covariates did seem to have an influence on the pharmacokinetics of meropenem. 181	
When every covariate was tested within the model in a stepwise procedure, the following ones were found to significantly 182	
affect the pharmacokinetics of meropenem: serum albumin on V (ΔOFV=-147.05, run 021), gender on Cl (ΔOFV=-183	
155.44, run 031), patients’ age on V (ΔOFV=-162.95, run 033) and, finally, sepsis on Cl (ΔOFV=-169.44, run 059). The 184	
improvement in goodness-of-fit plots witnessed the leverage of those covariates on drug pharmacokinetics (Figure 1), 185	
although the presence of over- and under-prediction over time are detectable and they likely depend on the 1-compartment 186	
model (Figure 1D). Furthermore, an exponential relationship was chosen for patients’ age and serum albumin, because it 187	
gave the better results in terms of standard errors, residuals and goodness-of-fit plots with respect to other kinds of linear 188	
and non-linear relationships. However, it is worth noting that other possible covariates failed to improve the fitting of 189	
observed data despite a strong mechanistic and physiologic rationale and the variability among the present patients (Table 190	
1) supported their inclusion within the model as already published [30]. In particular, the introduction of serum creatinine 191	
(ΔOFV=-89.70, run 009) and creatinine clearance (ΔOFV=-108.80, run 011) did not improve the fitting performance of 192	
the model without covariates (i.e., ΔOFV=-116.40, run 007). Values of fixed and random effects, together with bootstrap 193	
results are presented in Table 2. The final model was as follows: 194	
Cl=THETA(1)×[1+THETA(4)]×[1+THETA(6)] × ETA(1) 195	
V=THETA(2)×[(ALB/22)×EXP(THETA(3))]×[(AGE/61)×EXP(THETA(5))] × ETA(2) 196	
where THETA(4) was 1 for men and 1.760 for women, while THETA(6) was 0.427 or 1 in the presence of sepsis or 197	
severe sepsis/septic shock, respectively. ALB and AGE are serum albumin and patients’ age, respectively, while ETA(1) 198	
and ETA(2) represent the IIV for Cl and V of meropenem, respectively. It is worth noting that meropenem clearance in 199	
women was greater than that measured in men (approximately, 38%). That gender-based difference in the 200	
pharmacokinetics of drugs is not usual, and it likely reflects the large interpatient variability in a limited number of 201	
patients. Indeed, women had a higher drug clearance but that difference was not statistically different because the large 202	
interpatient variability (i.e., coefficient of variability of Cl in men and women accounted for 27.4% and 57.3%, 203	
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respectively). Therefore, the relationship between gender and drug clearance does serve to improve the fitting of the 204	
observed data in the present population of patients, while the analyses in a larger group of individuals could confirm or 205	
deny the relationship itself. 206	
Furthermore, the IIV values of Cl and V decreased from 82.24% and 102.47% up to 44.39% and 66.51%, respectively, 207	
while the corresponding η-shrinkage values in the final model accounts for 4.22% and 8.16%. The goodness of the final 208	
model to fit individual plasma concentration profiles was demonstrated by values of main pharmacokinetic parameters 209	
(Table 3) that are similar to those already published in the literature [31], and further sustained by the bootstrap and VPC 210	
analyses (Table 2 and Figure 2). 211	
The simulation of minimum plasma concentrations of meropenem returned mean±SD values ranging from 3.11±4.80 212	
mg/L up to 33.57±18.61 mg/L for a 5-h extended infusion of 1 g every 12 hours or a continuous infusion of 6 g/day, 213	
respectively. Figure 3 presents PTA curves for both fT>MIC and fCmin>4×MIC PK/PD parameters across the entire 214	
distribution of K. pneumoniae MIC values obtained from EUCAST [26]. Furthermore, Table 4 reports CFR values 215	
obtained on the basis of simulation for different therapeutic schedule. In particular, 5-h extended infusions were simulated 216	
according to the maximum time length of meropenem solution stability at room temperature (5.15 h) [32]. Results clearly 217	
show that the highest probability to achieve pre-defined target values both in terms of fT>MIC and fCmin>4×MIC was 218	
associated with the shorter time interval between two consecutive doses (i.e., 8 h). On the basis of this observation, 219	
simulated continuous infusions of meropenem for total daily doses of 3 and 6 g led to an improvement in fCmin>4×MIC 220	
values when compared with those obtained after 3-h and 5-h extended infusions. Furthermore, trough values after 221	
continuous infusions remain above the 95% threshold up to MIC values of 4 and 8 mg/L, respectively. These results 222	
suggest that although the fT>MIC values between extended and continuous infusions do not change in the present 223	
simulation, continuous infusions nearly abolished plasma concentration fluctuations, hence ensuring the achievement of 224	
higher Cmin values and consequently CFR values (Table 4). 225	
 226	
Discussion 227	
In the present study, we found that continuous i.v. infusions of meropenem at doses of 6 g/day seems to be more effective 228	
than standard regimens (1-3 g twice or thrice per day as 3-h i.v. infusions) to achieve target PK/PD values. 229	
Meropenem remains a suitable choice for treatment of severe infections in critically ill patients because it exerts a time-230	
dependent killing against both Gram-positive and Gram-negative bacterial strains. However, several factors may 231	
significantly influence meropenem pharmacokinetics, hence exposing the patient to a non-negligible risk of treatment 232	
failure especially when severe or life-threatening infections are diagnosed. The present study identified significant 233	
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covariates that may influence meropenem disposition in ICU patients affected by K. pneumoniae infection thus improving 234	
the stratification of patients according to their risk of receiving suboptimal treatments. 235	
It is worth noting that sepsis is considered a hyperdynamic condition associated with an increased clearance of drugs and 236	
their corresponding volume of distribution [11]. Furthermore, drug disposition may display a large inter- and intra-237	
individual variability due to the severity of the sepsis and or the general clinical conditions of patients [33]. However, in 238	
a previous study [34], fifteen critically ill patients who received meropenem 1000 mg twice a day as a 30-min i.v. infusion 239	
had lower values of clearance and volume of distribution with respect to those measured in the present ones, despite the 240	
severity of infection was similar according to Charlson and SAPS II scores. That difference still remains also when the 241	
comparison is made considering those of our patients that received meropenem 1000 mg 2 or 3 times per day. It is likely 242	
that the limited number of patients and their variable clinical conditions could be claimed as responsible for these 243	
discrepancies. Indeed, the severity of infection (i.e., sepsis versus severe sepsis or septic shock) was identified as having 244	
a leverage on drug clearance in our model, because individuals with septic shock or severe sepsis showed an increase in 245	
drug clearance with respect to the remaining individuals (9.71±4.61 vs. 8.96±4.45 L/h, respectively). However, the 246	
difference in Cl between the two groups was not significant because of the large variability (CV%, 47.5-49.6%). At the 247	
same time, V was increased in the presence of severe sepsis or septic shock. Intriguingly, another smaller study performed 248	
in 9 patients found Cl and V mean values lower than the present one [35], and the severity of the infection was not 249	
identified as a significant covariate for meropenem pharmacokinetics. Therefore, the present results are suggesting for 250	
the first time that the severity of the infection should be taken into account to choose the most appropriate dose of 251	
meropenem, and this is the most important difference with respect to previous works [34,35]. Furthermore, the large inter-252	
patients variability in the pharmacokinetics of meropenem does suggest the adoption of therapeutic drug monitoring 253	
protocols. Finally, creatinine clearance has been identified as a significant covariate for drug clearance in several previous 254	
POP/PK models [14,30], but not in the present one. Although the differences listed above, the present values of main 255	
pharmacokinetics parameters are in agreement with those already published [31]. 256	
The administration of meropenem as continuous infusions allows the maintenance of plasma concentrations above the 257	
MIC for target organisms while it prevents the highest concentrations that may result in adverse reactions without an 258	
improvement in bactericidal activity [33,36]. In fact, simulated continuous i.v. infusions of meropenem 3-6 g/day nearly 259	
abolish plasma fluctuations and this fact allows the achievement of fCmin>4×MIC values above the 95% for K. 260	
pneumoniae strains whose MIC values are 4-8 mg/L. Furthermore, previous results demonstrated that patients with severe 261	
bacterial infections experienced a significantly greater clinical cure rate (82% vs. 33%; p=0.002) and bacteriological 262	
eradication (97% vs. 44%; p<0.001) when meropenem achieved T>MIC values ≥100% with respect to lower T>MIC 263	
values [37]. Therefore, plasma meropenem concentrations higher than MIC values for the entire dosing interval between 264	
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two consecutive administrations should be regarded as a mandatory goal for an effective and appropriate antimicrobial 265	
chemotherapy, as demonstrated in cystic fibrosis patients who received meropenem as continuous infusions at daily doses 266	
of 3 and 6 g [38]. Although continuous infusions may improve meropenem efficacy, the present model suggests that 267	
meropenem pharmacokinetics is significantly influenced by several factors, and highest doses should be used to achieve 268	
effective fCmin>4×MIC values in ICU patients. However, as pointed out by several Authors [37,39], the achievement of 269	
highest T>MIC and fCmin>4×MIC values are negatively influenced by the presence of bacteria strains with high MICs. 270	
Highest dosages are not usually prescribed for the augmented risk of toxic effects, hence the alternative and effective 271	
strategy is to use carbapenems in association with other drugs [40]. 272	
Finally, the present study shows some pitfalls that should be discussed. The small number of enrolled patients is a 273	
limitation even if it can offer interesting information about meropenem pharmacokinetics in critically ill patients with 274	
sepsis. Second, a resistant-vs.-sensitive output has been obtained by the Vitek2 system instead of the determination of 275	
actual MIC values, as it happens by using the broth micro-dilution or the E-test assays. However, the present study was 276	
aimed at simulating different dosing regimens rather than studying the PK/PD correlation in the enrolled patients. Third, 277	
in contrast with other antimicrobial drugs, such as vancomycin, meropenem solutions have a limited stability at room 278	
temperature [39]. This means that the carbapenem should be reconstituted at least 5 times a day to allow a continuous 279	
infusion, hence increasing the workload of caregivers. 280	
In conclusion, the present study suggests that continuous i.v. infusions of meropenem may have a greater probability than 281	
extended infusions (i.e., 3-5 h) to be effective in critically ill patients, and that the severity of the sepsis seems to influence 282	
the pharmacokinetics of the drug. However, the treatment of the less-sensitive bacterial strains requires 283	
polychemotherapies, which represent the most appropriate way to obtain a higher rate of clinical cure, to overcome 284	
treatment failures and to reduce the incidence of drug resistance.  Finally, the present study shows the wide interpatient 285	
variability in drug disposition among critically ill patients, and it strongly supports the adoption of therapeutic drug 286	
monitoring protocols for meropenem schedules.  287	
 288	
 289	
290	
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Table 1 291	
Descriptive statistics of covariates investigated in the present population of ICU patients and main clinical 292	
characteristics. Meropenem was administrated as 3-h i.v. infusions. 293	
 294	
Data are expressed as mean±standard deviation (median or range), or number of patients (percentage). *p<0.05, 295	
significant gender-based differences (unpaired Student’s t test). #, creatinine clearance was calculated according to the 296	
Cockcroft-Gault formula. 297	
APACHE II, Acute Physiology and Chronic Health Evaluation II; GSC, Glasgow Coma Scale; CHARLSON, comorbidity 298	
index score; SAPS II, Simplified Acute Physiology Score. 299	
 300	
  301	
    
Parameter All patients (n=27) Men (n=17) Women (n=10) 
    
    
Age (years) 62±12 (61) 60±13 (59) 54±11 (63) 
Body weight (kg) 76.2±30.3 (68) 86.1±31.8* (70) 61.8±22.0 (57) 
Height (cm) 170.3±7.3 (170) 173.7±6.1* (173.5) 165.3±6.1 (165) 
BSA (m2) 1.9±0.3 (1.8) 2.0±0.3* (1.9) 1.7±0.2 (1.7) 
BMI (kg/m2) 26.1±8.9 (23.4) 28.3±9.5 (24.3) 22.7±7.1 (21.5) 
Serum creatinine (mg/dL) 1.3±1.0 (0.9) 1.2±0.5 (1.2) 1.3±1.5 (0.7) 
Serum albumin (g/L) 24.3±6.6 (23.1) 24.2±5.8 (23.1) 24.3±7.8 (22.7) 
Creatinine clearance (mL/min) # 87.4±44.2 (82.9) 88.0±43.8 (82.9)  86.3±47.2 (79.0)  
Diuresis (mL/day) 2032±950 (2000) 2244±1079 (2100) 1723±650 (1650) 
    
Sepsis (n, percentage) 12, 44% 7 (41%) 5 (50%) 
Severe sepsis (n, percentage) 10 (37%) 8 (47%) 2 (20%) 
Septic shock (n, percentage) 2 (7.4%) 0 2 (20%) 
Mechanical ventilation (n, 
percentage) 
13 (48%) 8 (47%) 5 (50%) 
APACHE II 13±6 (4-25) 13±6 (4-25) 12±7 (4-24) 
GSC 12±4 (5-15) 12±3 (6-15) 11±5 (5-15) 
CHARLSON 5±3 (0-10) 4±3 (0-10) 5±3 (2-10) 
SAPS II 41±16 (10-93) 37±11 (10-59) 49±21 (28-93) 
    
Meropenem dosage (3-h i.v. infusions)   
1g x 2 2 2 0 
1g x 3 2 2 0 
2g x 2 5 2 3 
2g x 3 17 10 7 
3g x 3 1 1 0 
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Table 2 302	
Estimates of the final model and bootstrap results based on simulation of 4000 individuals.  303	
 304	
  Final model Bootstrap 
  
Value S.E. 
Median 
value 
95%CI 
OFV  590.294 n.a. 577.646 516.734 - 632.160 
Cl (L/h) THETA(1) 2.181 0.226 2.132 1.776 - 2.696 
V (L) THETA(2) 8.305 0.989 8.094 4.007 - 11.684 
ALB (mg/dL) THETA(3) 0.521 0.762 0.553 0.346 - 0.812 
SEX THETA(4) 
1 male 
1.760 female 
- 
0.669 
- 
1.709 
- 
0.658 - 3.521 
AGE (years) THETA(5) 0.517 0.409 0.550 0.360 - 0.807 
SEPSIS THETA(6) 
0.427 sepsis 
1 sev. sep. 
0.344 
- 
0.510 
- 
0.052 - 1.642 
- 
ERR PROP (%)  0.401 0.535 0.403 0.077 - 0.536 
ERR ADD (mg/L)  7.070 0.937 7.087 2.949 - 10.902 
IIVCL (%) ETA(1) 44.38 27.39 40.50 24.90 – 56.83 
IIVV (%) ETA(2) 66.48 34.35 64.58 44.94 – 87.41 
 305	
Final model was as follows: CL=THETA(1)×[1+THETA(4)]×[1+THETA(6)]×ETA(1) and 306	
V=THETA(2)×[(ALB/22)×EXP(THETA(3))]×[(AGE/61)×EXP(THETA(5))]×ETA(2), where THETA(4) was 1 for men 307	
and 1.760 for women, while THETA(6) was 0.427 or 1 in presence of sepsis or severe sepsis/septic shock, respectively. 308	
OFV, objective function value; Cl, clearance; V, volume of distribution; ALB, serum albumin; SEX, gender; AGE, age 309	
of patients; SEPSIS, severity of infection (sepsis vs. severe sepsis/septic shock); ERR PROP, proportional error; ERR 310	
ADD, additive error; IIVCl and IIVV, interindividual variability in clearance and volume of distribution, respectively. 311	
 312	
  313	
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Table 3 314	
Mean values of pharmacokinetic parameters as obtained by the final model. 315	
 316	
 Cl V t1/2 Cmin 
 (L/h) (L) (h) (mg/L) 
All patients 
(n=27) 
9.38±4.47 
(8.34) 
26.20±14.56 
(20.41) 
2.22±1.51 
(1.62) 
7.90±7.91 
(5.03) 
     
Men 
(n=17) 
8.24±2.26 
(8.14) 
25.53±14.81 
(20.41) 
2.26±1.43 
(1.62) 
8.83±8.51 
5.07 
     
Women 
(n=10) 
11.31±6.48 
(9.49) 
27.35±14.83 
(23.89) 
2.16±1.73 
(1.28) 
6.31±6.88 
(3.48) 
 317	
Results are expressed as mean±standard deviation (median) values. Cl, clearance; V, volume of distribution; t1/2, 318	
terminal elimination half-life; Cmin, minumum plasma concentration. 319	
 320	
  321	
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Table 4 322	
Cumulative fraction of response (CFR) values for fT>MIC and Cmin>4×MIC according to the different treatment 323	
schedules of meropenem administration simulated by using the final pharmacokinetic model. In bold CFR values higher 324	
than 95%. 325	
 326	
 327	
CFR Treatment schedules of meropenem administration (daily doses) 
 i.v. infusions 
 3 h  5 h  continuous 
 1 g x 2 1 g x 3 2 g x 2 2 g x 3  1 g x 3 2 g x 3  3 g 6 g 
           
fT>MIC 93.9 97.6 95.1 98.2  97.6 98.2  97.6 98.2 
Cmin>4×MIC 66.7 85.0 71.9 88.0  96.5 97.5  99.8 100.0 
	328	
	329	
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participants included in the study. 334	
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 338	
Headings 339	
- Meropenem pharmacokinetics is highly variable in ICU patients with severe infections, and some patients do not achieve 340	
effective meropenem plasma concentrations. 341	
- The severity of infection does influence the pharmacokinetics of meropenem. 342	
- Meropenem efficacy could be increased by the adoption of continuous infusions. 343	
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Figure legends 449	
Figure 1. Goodness-of-fit plots of the final population pharmacokinetic model obtained simulating 1000 datasets on the 450	
basis of the original dataset as a template. Population (A) and individual prediction (B) plots are presented together with 451	
absolute individual weighted residual (|iWRES|) versus individual predictions (C) and weighted residuals (WRES) versus 452	
time after dose (D) graphs. Black thin and thick lines, lines of identity and linear regression lines (A and B) or loess line 453	
(C), respectively. Plots show lines of identity (black thin lines, A) and linear regression lines (black thick lines, B) and 454	
loess line (black thick lines, C and D). 455	
 456	
Figure 2. Prediction-corrected visual predictive checks (90% prediction interval) based on the final population 457	
pharmacokinetic model superimposed on prediction-corrected observed meropenem plasma concentrations. The figure 458	
shows the observed data (dots), the median, 5th and 95th percentile of the observed data (lines) and the 95% confidence 459	
intervals around the simulated median (dark grey) and 5th and 95th percentiles (light grey). 460	
 461	
Figure 3. Probability of target attainment for fT>MIC (A) and fCmin>4×MIC (B) in 4000 simulated patients, according to 462	
the investigated schedules of meropenem administration and MIC values distribution obtained from EUCAST. Filled 463	
symbols, 3-h i.v. infusions of 1 g x 2 (square), 1 g x 3 (triangle), 2 g x 2 (circle) and 2 g x 3 (diamond). Open symbols, 5-464	
h i.v. infusions of 1 g x 3 (circle) and 2 g x 3 (diamond) or continuous i.v. infusions of 3 g/day (triangle) and 6 g/day 465	
(square). 466	
 467	
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Supplementary Material 474	
 475	
Measurement of meropenem plasma concentrations  476	
 477	
Meropenem plasma concentrations were determined with a validated HPLC method previously described by Legrand et 478	
al. [18]. Meropenem was purchased from Sigma-Aldrich (Milano, Italy) and all reagents were of HPLC grade and were 479	
purchased from Merck (Darmstadt, Germany) and Sigma-Aldrich (Milano, Italy). The filtration system was obtained 480	
from Millipore S.p.A. (Milano, Italy). A KromaSystem 2000 HPLC system consisting of a 325 pump system, a 535 UV 481	
detector, and signal integration software (BIO-TEK Instruments s.r.l., Milano, Italy) was used. Calibration samples were 482	
prepared in pooled samples of blank human plasma, obtaining final concentrations ranging from 0.5 to 100 mg/L. Clinical 483	
samples, blank, calibration standards quality controls (QC) were extracted using this method. An aliquot of each extracted 484	
sample (50 µL) was injected into a C18 Lichrosphere column 250 mm x 4.5 mm (Merck KGaA Darmstadt, Germany) and 485	
eluted at 35 °C with a mobile phase (at pH 6.5) consisting of phosphate buffer (0.06 M potassium dihydrogen phosphate 486	
- 0.01 M disodium hydrogen phosphate) and acetonitrile (93:7, v/v). The flow rate was 1 mL/min and the UV detector 487	
was set at 298 nm (ABS 0.1, RT 0.1). Each chromatographic run lasted 15 min. 488	
The results obtained from the analysis of the calibration points were analysed by linear regression. In order to assess 489	
whether a calibration point could be accepted, it was back-calculated on the basis of the equation of the corresponding 490	
calibration curve; a calibration curve was rejected if more than two concentrations or two adjacent concentrations deviated 491	
more than 20% from the nominal value for the low limit of quantification (LLOQ) and by more than 15% for the other 492	
concentrations (outliers). The precision and accuracy of the method were determined by performing replicate analyses of 493	
QC plasma samples (1, 5, 25 mg/L) and LLOQ (0.5 mg/L). Two replicates of each QC and LLOQ were analyzed on 3 494	
different days and subjected to within- and between-run analysis. Samples with concentrations higher than the upper limit 495	
of the calibration were reanalyzed by dilution of the sample. The precision (relative standard deviation of replicate 496	
analysis) was calculated using the ANOVA test. The accuracy of the method was calculated by the following formula: 497	
BIAS = (mean–nominal concentration)/(nominal concentration × 100). 498	
 499	
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 501	
Supplemental Table 1 502	
Distribution of MIC values for meropenem with respect to isolated K. pneumoniae strains (EUCAST)	503	
	504	
MIC (mg/L) Number of strains 
0.008 271 
0.016 989 
0.32 2878 
0.064 11766 
0.125 1017 
0.25 354 
0.5 187 
1 128 
2 78 
4 49 
8 32 
16 33 
32 4 
64 1 	505	
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Simulation of meropenem plasma concentrations: additional information 507	
 508	
Meropenem plasma concentrations were simulated according to the final model. In particular, at every round of 509	
simulation, sex and severity of sepsis were chosen in a random manner by appropriate command lines included within 510	
the NONMEM control file. In a similar way, patient’s age and serum albumin values were obtained according to value 511	
distribution of the corresponding parameter in the original population enrolled in the present study. 512	
Final  513	
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